121 results about "Phage Display Techniques" patented technology

Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

The invention belongs to the field of biotechnology, and specifically, relates to a tumor-targeting double-drug carrying and delivery system and a preparation method thereof. The tumor-targeting double-drug carrying and delivery system adopts high-molecular materials, polyethylene glycol, a polypeptide, a treatment gene and a chemotherapeutic drug, wherein the polypeptide is utilized as a targeting head and the high-molecular materials are utilized as base high-molecular carriers. The preparation method comprises that the chemotherapeutic drug of adriamycin and the like are inserted into double chains of the treatment gene to form a gene-chemotherapeutic drug compound; and through electrostatic interaction between the gene chemotherapeutic compound and the base high-molecular carriers, the tumor-targeting double-drug carrying and delivery system which simultaneously carries the treatment gene and the chemotherapeutic drug is obtained. The high-molecular materials are novel polypeptide-modified high-molecular materials, are selected by a phage display technology, and can enter into cells by endocytosis, and thus the gene and chemotherapeutic drug intake capability of tumor cells are improved and safety is improved. The polypeptide (T7) as the targeting head has advantages belonging to transferrin, can effectively avoid interferences from endogenous transferrin, has high targeting and treatment efficiency, is easy for preparation, and can be further developed and be utilized for targeting treatment on other tumor tissue.